Cargando…

Time‐Dependent Risk of Cardiovascular Events Following an Exacerbation in Patients With Chronic Obstructive Pulmonary Disease: Post Hoc Analysis From the IMPACT Trial

BACKGROUND: The association between chronic obstructive pulmonary disease exacerbations and increased cardiovascular event risk has not been adequately studied in a heterogenous population with both low and high cardiovascular risk. METHODS AND RESULTS: This post hoc analysis of the IMPACT (Informin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dransfield, Mark T., Criner, Gerard J., Halpin, David M. G., Han, MeiLan K., Hartley, Benjamin, Kalhan, Ravi, Lange, Peter, Lipson, David A., Martinez, Fernando J., Midwinter, Dawn, Singh, Dave, Wise, Robert, Kunisaki, Ken M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9683674/ https://www.ncbi.nlm.nih.gov/pubmed/36102236 http://dx.doi.org/10.1161/JAHA.121.024350

Ejemplares similares

Effect of chronic mucus hypersecretion on treatment responses to inhaled therapies in patients with chronic obstructive pulmonary disease: Post hoc analysis of the IMPACT trial
por: Thompson, Philip J., et al.
Publicado: (2022)

The effect of exacerbation history on outcomes in the IMPACT trial
por: Halpin, David M.G., et al.
Publicado: (2020)

Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease
por: Lipson, David A., et al.
Publicado: (2020)

InforMing the PAthway of COPD Treatment (IMPACT) trial: fibrinogen levels predict risk of moderate or severe exacerbations
por: Singh, Dave, et al.
Publicado: (2021)

The Effect of Inhaled Corticosteroid Withdrawal and Baseline Inhaled Treatment on Exacerbations in the IMPACT Study. A Randomized, Double-Blind, Multicenter Clinical Trial
por: Han, MeiLan K., et al.
Publicado: (2020)

Triple Versus Dual Combination Therapy in Chronic Obstructive Pulmonary Disease in Asian Countries: Analysis of the IMPACT Trial
por: Halpin, David M. G., et al.
Publicado: (2020)

Risk of Exacerbation and Pneumonia with Single-Inhaler Triple versus Dual Therapy in IMPACT
por: Dransfield, Mark T., et al.
Publicado: (2021)

Discordant diagnostic criteria for pneumonia in COPD trials: a review
por: Wise, Robert A., et al.
Publicado: (2021)

Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT Study
por: Tabberer, Maggie, et al.
Publicado: (2020)

Prognostic value of clinically important deterioration in COPD: IMPACT trial analysis
por: Han, MeiLan K., et al.
Publicado: (2021)

Benralizumab Prevents Recurrent Exacerbations in Patients with Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis
por: Singh, Dave, et al.
Publicado: (2023)

Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial
por: Day, Nicola C., et al.
Publicado: (2020)

Reply to López-Campos et al.: Triple-Therapy Trials for Chronic Obstructive Pulmonary Disease: Methodological Considerations in the Mortality Effect
por: Lipson, David A., et al.
Publicado: (2021)

Leveraging Omics to Predict Chronic Obstructive Pulmonary Disease Exacerbations: The “Immunome”
por: Polverino, Francesca, et al.
Publicado: (2023)

Measuring disease activity in COPD: is clinically important deterioration the answer?
por: Singh, Dave, et al.
Publicado: (2020)

Correction to: Measuring disease activity in COPD: is clinically important deterioration the answer?
por: Singh, Dave, et al.
Publicado: (2021)

Single-inhaler triple therapy in symptomatic COPD patients: FULFIL subgroup analyses
por: Halpin, David M.G., et al.
Publicado: (2018)

Reply to Wang and Lai: The Role of Eosinophils during the Withdrawal of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease
por: Han, MeiLan K., et al.
Publicado: (2021)

Impact of prior and concurrent medication on exacerbation risk with long-acting bronchodilators in chronic obstructive pulmonary disease: a post hoc analysis
por: Naya, Ian, et al.
Publicado: (2019)

Single-Inhaler Triple Therapy in Patients with Advanced COPD: Bayesian Modeling of the Healthcare Resource Utilization Data and Associated Costs from the IMPACT Trial
por: Gabrio, Andrea, et al.
Publicado: (2022)

Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease
por: Halpin, David M. G., et al.
Publicado: (2021)

β-Blockers for the prevention of acute exacerbations of chronic obstructive pulmonary disease (βLOCK COPD): a randomised controlled study protocol
por: Bhatt, Surya P, et al.
Publicado: (2016)

Cost-Effectiveness Of Once-Daily Single-Inhaler Triple Therapy In COPD: The IMPACT Trial
por: Ismaila, Afisi S, et al.
Publicado: (2019)

The Association Between Rate and Severity of Exacerbations in Chronic Obstructive Pulmonary Disease: An Application of a Joint Frailty-Logistic Model
por: Sadatsafavi, Mohsen, et al.
Publicado: (2016)

Effect of beta-blockers on exacerbation rate and lung function in chronic obstructive pulmonary disease (COPD)
por: Duffy, Sean, et al.
Publicado: (2017)

Serum bilirubin and the risk of chronic obstructive pulmonary disease exacerbations
por: Brown, Kirstin E., et al.
Publicado: (2017)

Epigenetic marker of telomeric age is associated with exacerbations and hospitalizations in chronic obstructive pulmonary disease
por: Hernández Cordero, Ana I., et al.
Publicado: (2021)

Validation of the Summit Lab Score in Predicting Exacerbations of Chronic Obstructive Pulmonary Disease Among Individuals with High Arterial Stiffness
por: Horne, Benjamin D, et al.
Publicado: (2021)

One More Time: The Impact of Inhaled Corticosteroid Withdrawal on IMPACT
por: Han, MeiLan K., et al.
Publicado: (2020)

International Differences in the Frequency of Chronic Obstructive Pulmonary Disease Exacerbations Reported in Three Clinical Trials
por: Calverley, Peter M. A., et al.
Publicado: (2022)

Effect of Recent Exacerbation History on the Efficacy of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease in the FULFIL Trial
por: Panettieri Jr, Reynold A, et al.
Publicado: (2022)

Self-reported sleep quality and acute exacerbations of chronic obstructive pulmonary disease
por: Geiger-Brown, Jeanne, et al.
Publicado: (2015)

Club Cell Secretory Protein (CCSP) is Reduced in Hospitalized Chronic Obstructive Pulmonary Disease (COPD) Exacerbations
por: Baldomero, Arianne K, et al.
Publicado: (2020)

Frequency of Exacerbations in COPD: An Analysis of the SPIROMICS Cohort
por: Han, MeiLan K., et al.
Publicado: (2017)

Differential DNA methylation marks and gene comethylation of COPD in African-Americans with COPD exacerbations
por: Busch, Robert, et al.
Publicado: (2016)

Risk factors for COPD exacerbations in inhaled medication users: the COPDGene study biannual longitudinal follow-up prospective cohort
por: Busch, Robert, et al.
Publicado: (2016)

Reply to Suissa: Mortality in IMPACT: Confounded by Asthma?
por: Lipson, David A., et al.
Publicado: (2020)

Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary
por: Agustí, Alvar, et al.
Publicado: (2023)

Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary
por: Agustí, Alvar, et al.
Publicado: (2023)

Mannose-binding lectin deficiency and acute exacerbations of chronic obstructive pulmonary disease
por: Albert, Richard K, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_rt68c3jcm7erm140pvbsr65u2r